David E. Selk

Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.

Gina M. Bores, Francis P. Huger, Wayne W. Petko et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 247 citations

On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia

Mark D. Black, David E. Selk, Janice M. Hitchcock et al. · Neuropharmacology · 1999 · 84 citations

Psychiatry, Psychotic Disorder, Synthase Inhibition +9

Pharmacological Activity and Safety Profile of P10358, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer’s Disease

Craig P. Smith, Gina M. Bores, Wayne W. Petko et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 35 citations

Synthesis and Evaluation of 5-Amino-5,6,7,8-tetrahydroquinolinones as Potential Agents for the Treatment of Alzheimer's Disease

David M. Fink, Gina M. Bores, Richard C. Effland et al. · Journal of Medicinal Chemistry · 1995 · 31 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Bioorganic Chemistry +15

Synthesis and preliminary structure-activity relationships of 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1H-indol-5-yl methyl carbamate (P10358), a novel acetylcholinesterase inhibitor

Lawrence L. Martin, Larry J. Davis, Joseph Klein et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 21 citations

Medicinal Chemistry, Biochemistry, Natural Sciences +8